Amanta Healthcare manufactures and sells sterile liquid medicines, including IV fluids and respiratory solutions, using specialized plastic molding technologies for both domestic hospitals and international markets.
The company possesses a narrow moat based on its early adoption of ISBM technology for two-port IV systems (SteriPort), which offers superior sterilization (121°C) and drug compatibility compared to standard polyethylene containers. While this provides pricing power in critical care niches, the overall low net margins (1.5%) and high competition in the broader LVP market suggest the moat is limited to specific high-value therapeutic segments.
Management has prioritized deleveraging, reducing debt-to-equity from over 3x to near 1x, while reinvesting in high-margin SteriPort capacity and a captive solar plant to lower energy costs. However, the historical ROE is deeply negative, indicating that past capital deployment has yet to yield consistent bottom-line value for shareholders.
The investment collapsed as the company's razor-thin 1.5% net margins proved insufficient to absorb rising input costs and interest burdens from its 1.11 debt-to-equity ratio. Despite the SteriPort technology, the business remained a commodity-adjacent manufacturer trapped in a capital-intensive cycle, where high working capital needs (141 days) and single-site concentration in Gujarat led to a liquidity crunch when Line 3 delays persisted. The historical -38.9% ROE was not a temporary anomaly but a warning of structural inability to generate shareholder value, eventually leading to a permanent impairment of capital as the business failed to outrun its debt.
RichFakir rates Amanta Healthcare Ltd's business quality as mediocre — 42/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Amanta Healthcare Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Amanta Healthcare Ltd is: Not rated. A mediocre business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Amanta Healthcare Ltd's fair value is about ₹45 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →